Starch Capsules Market Analysis

Distribution Channel Segment Analysis

Direct sales are leading the segment and is poised to hold the highest share value of 70.1% by 2035. Direct sales is dominated by starch capsules, as they are a bulk industrial ingredient. The OEC report in 2023 has stated that U.S. holds over 19.9% of the global pharmaceutical ingredient import share, including starch-based capsules. This segment is the dominant model over fragmented retail distribution for this market because it guarantees supply chain efficiency, improved quality, and cost-effectiveness for large-volume purchases.

End user Segment Analysis

The pharmaceutical & nutraceutical companies sub-segment leads as the major end-user. This is stimulated by high in-house manufacturing of capsule-based drugs and supplements. According to the U.S. Food and Drug Administration (FDA), the number of new drug applications (NDAs) specifying plant-based excipients increased between 2022 and 2024. Further, the SV Healthcare report in 2024 has stated that India’s nutraceutical market is expanding and is poised to reach USD 18 billion by the end of 2025. This indicates a strategic decision by leading companies to respond to consumer demand for vegetarian products, investing heavily in R&D and securing up their leading revenue share through controlled, bulk manufacturing.

Application Segment Analysis

The pharmaceuticals segment is expected to garner the largest share in the starch capsules market by the end of 2035. The dominance of the segment is attributable to the widespread preference over tablets for pediatric and aging populations. In this regard NIH report in 2024 states that new molecular entities require capsule delivery systems in pharmaceuticals. Besides, in 2023 EMA reported that the plant-based capsules obtain faster regulatory approval thus denoting a positive outlook for segment’s dominance.

Our in-depth analysis of the global market includes the following segments: